Gelteq Limited Closes US$5.2 Million Initial Public Offering NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of...

Gelteq Limited Prices US$5.2 Million Initial Public Offering NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of...

Gelteq Strengthens Partnership with Monash Innovation Labs MELBOURNE, Australia, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing...

Gelteq Granted First U.S. Patent for Gel-based Blood Glucose Testing Product and Methodology MELBOURNE, Australia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition and sports, has been granted a U.S. patent (No....

Gelteq Appoints Seasoned Pharma and Tech Executive, James Pekarsky, as Chief Financial Officer MELBOURNE, Australia, July 22, 2021 (GLOBE NEWSWIRE) -- Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition and sports, has appointed James Pekarsky as chief...